Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of blood cancer (like AML, CML, MDS, MPN, ALL, or lymphoma) that is under control (less than 5% blasts in bone marrow or in remission).
- Your heart, lungs, liver, and kidneys work well enough for a transplant (heart pumps at least 50%, lungs function at least 50%, liver and kidney numbers in range).
- You have a suitable donor: a matched sibling, an unrelated donor that matches at least 7 out of 8 HLA markers, or a half-matched family donor.
- You have not had a stem cell transplant before.
- You are willing to use effective birth control for at least 12 months after transplant (for men) or 12-24 months (for women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Hear when a new Allogeneic Stem Cell Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.